ACLY and autoimmune polyendocrinopathy: Nevertheless, they are not considered as standardized ELISA, and, therefore, are not recommended with the following note: “if no options exist beside the use of automated-platform results for APS research, researchers should direct efforts to identifying and validating moderate/high thresholds of their platform, correlating it with aCL/anti-β2GPI ELISA moderate/high thresholds.” [3].